You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Reactions to honeybee stings: an allergic prospective

Brown, Tyson C.

Erratum

Current Opinion in Allergy and Clinical Immunology 2013, 13:365–371

The August 2013 article by Tyson C. Brown entitled ‘Reactions to honeybee stings: an allergic prospective’ [1] contained several errors in the article as a result of an oversight at the publisher's office for which we apologise. The corrected article is now available online at www.co-allergy.com.

Current Opinion in Allergy and Clinical Immunology. 13(5):587, October 2013.

Current Opinion in Allergy & Clinical Immunology:
doi: 10.1097/ACI.0b013e3283625144
ANAPHYLAXIS AND INSECT ALLERGY: Edited by Theodore Freeman and Ralf Heine
Abstract

Purpose of review: The purpose of this article is to provide a brief overview of the events involved in honeybee allergy and to concisely update the reader on progress toward knowledge of honeybee venom (HBV), strides in solving diagnostic difficulties, and advancements in improving safety and efficacy of HBV immunotherapy.

Recent findings: It is well known that honeybee allergy is unique in venom allergen and protein composition, diagnostic challenges, and immunotherapy safety and efficacy. Many new honeybee allergens have been recognized. Advances in testing, evaluation, and extract manipulation methods, many using recombinant technology, have allowed a greater ability to help with honeybee allergy diagnosis and resultant improvement in immunotherapy safety and evaluation of immunotherapy efficacy.

Summary: In an effort to address many honeybee allergy concerns, specific advances have been recently made. Some recently characterized honeybee allergens appear to be major contributors to honeybee allergy. In the setting of double-positivity, cross-reacting carbohydrate determinants and other cross-reacting components in HBV have made diagnosis of honeybee allergy challenging. Recombinant technology, including component-resolved diagnostics, and other evolving testing methods should help clarify double-positivity, if not now, in the very near future. Purified HBV and possibly depot formulations for immunotherapy appear to make it more well tolerated. Recombinant methods may help with evaluation of immunotherapy's safety and efficacy.

Author Information

Department of Medicine, Allergy/Immunology Clinic, Keesler Medical Center, Biloxi, Mississippi, USA

Correspondence to Tyson C. Brown, MD, Major, USAF, MC, Allergy/Immunology Clinic, Keesler Medical Center, 301 Fisher St., Keesler AFB, Biloxi, MS 39534, USA. Tel: +1 228 376 3550; e-mail: tyson.brown@us.af.mil

Copyright © 2013 Wolters Kluwer Health, Inc. All rights reserved.